Nutritional Sciences

The Korean Nutrition Society (한국영양학회)
권호 표지

Effects of a Selective COX-2 Inhibitor Celecoxib and Soy-Isoflavones on Molecular Markers Related to Apoptosis, and COX-2 and Mapkinase Expression in Estrogen-Fed Rats

  • Kim, Tae-Kyung (Department of Food and Nutrition, Hannam University) ;
  • Park, Ock Jin (Department of Food and Nutrition, Hannam University)
  • Published : 2005.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

The present study examined the effects of cyclooxygenase-2 (COX-2) inhibitor celecoxib or soy-isoflavones in the presence of estrogen on apoptosis related gene expression, COX-2 and mapkinase in 48-week old female rats. Expressions of bel-2 and bax proteins, which are known to be involved in the regulation of apoptosis, were investigated in mammary glands and heart tissues. The elevated expression of bel-2 expression was observed in mammary glands of celecoxib supplemented rats as well as soy-isoflavones. The mammary glands bel-2/bax ratio was found to be higher in celecoxib or soy-isoflavones supplemented rats. However, in heart tissues, expression of bel-2 and bax was in the order of control, celecoxib and soy-isoflavones. The up-regulation of COX-2 was observed in celecoxib or soy-isoflavones in mammary glands. 'The similar trend was not displayed with the mapkinase expression. In heart tissues, the down-regulation of COX-2 as well as mapkinase was observed in celecoxib or soy-isoflavones supplemented rats. Soy-isoflavones and celecoxib both had a similar regulatory pattern of bel-2, bax and COX-2 in mammary glands, and in heart tissues, only COX-2 exhibited a similar down-regulatory properly. These findings revealed that in estrogen sufficient state, celecoxib and soy-isoflavones might not exhibit proapoptotic potential or COX-2 inhibition in normal mammary glands.

Keywords

References

  1. Brzozowski AM, Pike CW, Pauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758, 1997 https://doi.org/10.1038/39645
  2. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H. Urinary excretion of lignins and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional diet. Am J Clin Nutr 54:1093-1100,1991
  3. Lee H P, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast cancer risk in Singapore. Lancet 336: 1197-1200, 1991
  4. Ziegler RG, Hoover RN, Pike MC. Migration patterns and breast cancer risk in Asian-American women. J Nat Cancer Inst 85:1819-1827, 1993 https://doi.org/10.1093/jnci/85.22.1819
  5. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 350:990-994,1997 https://doi.org/10.1016/S0140-6736(97)01339-1
  6. Zheng W, Dai Q, Custer L, Shu XO, Wen WQ, Jin F, Franke AA. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomark Prev 8:35-40, 1999
  7. Kroemer G. The proto-oncogene BcI-2 and its role in regulation apoptosis. Nature Med 3:614-620, 1997 https://doi.org/10.1038/nm0697-614
  8. Reed JC BcI-2:Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451-474, 1995
  9. Xu ZW, Friess H, buchler MW, Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 49:504-510, 2002 https://doi.org/10.1007/s00280-002-0435-5
  10. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18:3166-3172, 1999 https://doi.org/10.1038/sj.onc.1202650
  11. Cao Y, Prescott SM. Many actions of Cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190:279-286, 2002 https://doi.org/10.1002/jcp.10068
  12. Williams CS, Mann M, DuBois RN. The role of cyclo­oxygenases in inflammation, cancer and development. Oncogene 18:7908-7916, 1999 https://doi.org/10.1038/sj.onc.1203286
  13. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7:207-222, 2003 https://doi.org/10.1111/j.1582-4934.2003.tb00222.x
  14. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 28:127-142, 2004 https://doi.org/10.1016/j.cdp.2003.12.005
  15. Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113:803-810, 2005 https://doi.org/10.1002/ijc.20639
  16. Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, McComb RD, Roy SK, Shull JD. Rat strain-specific actions of $17{\beta}$-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci, 97:2779-2784, 2000
  17. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steriod Biochem 24:353-356, 1986 https://doi.org/10.1016/0022-4731(86)90080-4
  18. Li JJ, Li SA. Estrogen carcinogenesis in hamster tissues: role of metabolism. Fed Proc 46:1858-1863, 1987
  19. Kohli E, Zalrid M, Rogan E, Cavalieri EL. Greater reactivity of estradiol-3,4-quinone versus estradiol-2,3-quinone with DNA in the formation of depurinating adducts. Proc Am Assoc Cancer Res 44:180, 2003
  20. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogeous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 67:190-197, 1995
  21. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 76:401-405, 1997 https://doi.org/10.1038/bjc.1997.398
  22. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer risk in post-menopausal women: reanalysis of nine prospective studies. J Natl Cancer lnst 94:606-616,2002 https://doi.org/10.1093/jnci/94.8.606
  23. Thom DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83:2223-2235, 1998 https://doi.org/10.1210/jc.83.7.2223
  24. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 87:897-904, 1996
  25. Adlercreutz H, Mazur W. Phyto-estrogens and western diseases. Ann Med 29:95-120, 1997
  26. Shutt DA, Cox I. Steroid and phytoestrogen binding to sheep uterine receptors in vitro. J Endocrinol 52:299-310, 1972 https://doi.org/10.1677/joe.0.0520299
  27. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinol 103:1860-1867, 1978 https://doi.org/10.1210/endo-103-5-1860
  28. Wang TTY, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 17:271-275, 1996 https://doi.org/10.1093/carcin/17.2.271
  29. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose­dependent manner. Cancer Res 61:45-50, 2001
  30. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Fustafsson J, Nilsson S. Differential response of estrogen receptor ${\alpha}$ and estrogen receptor ${\beta}$ to partial estrogen agonists/antagonists. Mole Pharm 54:105-112, 1998
  31. Breinholt V, Hossaini A, Svendsen G, Brouwer C, Nielsen SE. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. Food Chem Toxicol 38:555-564, 2000 https://doi.org/10.1016/S0278-6915(00)00046-6
  32. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van der Saag PT, Van der Burg B, Gustafsson J. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor ${\beta}$. Endocrinol 139:4252-4263, 1998 https://doi.org/10.1210/en.139.10.4252
  33. Routledge EJ, White R, Parker MG, Sumpter JP. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) ${\alpha}$ and $ER{\beta}$. J BioI Chem 275: 35968-35993, 2000
  34. Shao A, Alpaugh ML, Fontana JA, Barsky SH. Geinstein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem 69:44-54, 1998 https://doi.org/10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.0.CO;2-V
  35. Tshilias J, Kapusta L, Slingerland J. The prognostic signi­ficance of altered cyclin-dependent kinase inhibitors in human cancer. Ann Rev Med 50:401-423, 1999 https://doi.org/10.1146/annurev.med.50.1.401
  36. Constatinou AI, Kamath N, Murley JS. Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur J Cancer 34:1927-1934, 1998 https://doi.org/10.1016/S0959-8049(98)00198-1
  37. Leung LK, Wang TT. Bcl-2 is not reduced in the death of MCF-7 cells at low genistein concentration. J Nutr 130:2922-2926, 2000
  38. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol BioI 65:169-174, 1998 https://doi.org/10.1016/S0960-0760(98)00021-1
  39. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxyg­enase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 696: 197-204, 1993
  40. Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson A W. The role of arachidonic acid oxygenation in pain and inflam­mation. Ann Rev lmmunol 2:335-357, 1984 https://doi.org/10.1146/annurev.iy.02.040184.002003
  41. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and diesease. FASEB J 12:1063-1073, 1998
  42. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin $H_{2}$ in the SHR aorta. Cir Res 76:1003-1010, 1993
  43. Dyer SM, Taylor DA, Bexis S, Hime NJ, Frewin DB, Head RJ. Identification of a non-endothelial cell thromboxane-like constrictor response and its interaction with the renin-angiotensin system in the aorta of spontaneously hypertensive rats. J Vasc Res 31:5-60, 1994
  44. Wong E, Huang J, Tagari P, Riendear D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157:393-402, 2001 https://doi.org/10.1016/S0021-9150(00)00756-5
  45. Baker CS, Hall RJ, Evans TJ. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc BioI 19:646-655, 1999 https://doi.org/10.1161/01.ATV.19.3.646
  46. Luscher TF, Aarhus LL, Vanhoutte PM. Indomethacin improves the impaired endothelium-dependent relaxations in small mesenteric arteries of the spontaneously hypertensive rats. Am J Hypertens 3:55-58, 1990
  47. Ghanam K, Lavagna C, Burgaud J-L, Javellaud J, Ea-Kim L, Oudart N. Involvement of cyclooxygenase 2 in the protective effect of 17 ${\beta}$-estradiol in hypercholesterolemic rabbit aorta. Biochem Biophy Resear Comm 275:696-703, 2000 https://doi.org/10.1006/bbrc.2000.3278